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Cutaneous B-cell lymphomas: 2013 update on diagnosis,
risk-stratification, and management
Ryan A. Wilcox*
Disease overview: Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally
classified into three distinct subgroups: primary cutaneous follicle-center lymphoma (PCFCL), primary cuta-
neous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type
(PCLBCL, LT).
Diagnosis: Diagnosis and disease classification is based on histologic review and immunohistochemical
staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary
to distinguish primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin
involvement.
Risk-stratification: Disease histology remains the most important prognostic determinant. Both PCFCL and
PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated
with an excellent long-term prognosis. In contrast, PCLBCL, LT is an aggressive lymphoma with an inferior
prognosis.
Risk-adapted therapy: PCFCL and PCMZL patients with solitary or relatively few skin lesions may be
affectively managed with local radiation therapy. Although single-agent rituximab may be employed for
patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast,
management of patients with PCLBCL, LT is comparable to the management of patients with systemic
DLBCL. Am. J. Hematol. 88:74–76, 2013. VC 2012 Wiley Periodicals, Inc.
Disease Overview
Primary cutaneous lymphomas are a heterogenous
group of extranodal non-Hodgkin lymphomas, approxi-
mately 25% of which are B-cell derived and are classified
into three major entities in the World Health Organization–
European Organization for Research and Treatment of
Cancer (EORTC) joint classification: primary cutaneous fol-
licle-center lymphoma (PCFCL), primary cutaneous diffuse
large B-cell lymphoma, leg type (PCLBCL, LT), and primary
cutaneous marginal zone lymphoma (PCMZL) [1]. The inci-
dence of cutaneous B-cell lymphomas (CBCL) has been
increasing and is currently 3.1 per million persons, based
on surveillance, epidemiology, and end results registry
data, with the highest incidence rates being reported
among males, non-Hispanic whites, and adults over the
age of 50 [2].
Diagnosis
Diagnosis and classification of a CBCL requires an
excisional or punch biopsy for careful morphologic and im-
munohistochemical analysis, and an appropriate staging
evaluation to exclude systemic disease [3]. The use of
appropriate immunohistochemical stains (e.g., CD5, cyclin
D1) may also aid in distinguishing CBCL from secondary
skin involvement by a systemic lymphoma.
PCFCL
PCFCL are commonly solitary plaques or tumors involv-
ing the trunk, particularly the head or scalp. Although
grouped lesions may be observed, multifocal disease is
less common. Histologically, PCFCL are characterized by a
follicular, diffuse, or mixed growth pattern comprised of
large centrocytes derived from germinal-center B-cells
[1,4,5]. In contrast to systemic follicular lymphomas, the
majority of PCFCL do not harbor the t(14;18) translocation
involving the bcl-2 locus, and do not strongly express bcl-2
by immunohistochemistry, although weak expression may
be observed in a minority of cases [6–8]. These CBCL
express bcl-6, variably express CD10, and are MUM-1/IRF-
4 negative, consistent with their origin from germinal-center
B cells.
PCLBCL, LT
In contrast to PCFCL, which is an indolent CBCL largely
involving the head and trunk commonly affecting middle-
aged adults, PCLBCL, LT commonly affects elderly females
and presents with rapidly progressive tumors involving the
lower legs. In contrast to PCFCL, these lymphomas are
characterized by diffuse sheets of centroblasts that highly
express bcl-2, likely due to gene amplification [9]. Most
cases are MUM-1/IRF-4 and bcl-6 positive, CD10 negative,
and have a gene expression profile resembling activated B
cells [5].
PCMZL
Patients with PCMZL frequently present with multifocal
patches, plaques or nodules involving the trunk and arms.
Although an association with Borrelia burgdorferi has been
observed in Europe, a similar association has not been
observed in cases from the United States [10–13]. PCMZL
are composed of a mixed infiltrate of small, marginal zone
B cells, lymphoplasmacytic cells, plasma cells, and reactive
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T cells. Marginal zone B cells characteristically express
bcl-2, but lack bcl-6 or CD10 expression.
Risk-Stratification
The International Society for Cutaneous Lymphomas
(ISCL) and EORTC recently proposed staging recommen-
dations for cutaneous lymphomas other than mycosis
fungoides and Sezary syndrome [3]. Staging should include
a history, physical examination, appropriate laboratory stud-
ies (including lactate dehydrogenase), and imaging (either
CT, PET, or increasingly PET/CT) of the chest, abdomen,
pelvis, and neck (in cases with involvement of the head or
neck). A bone marrow biopsy and aspirate should be
performed in cases of PCLBCL, LT. Although the ISCL/
EORTC does not endorse routine bone marrow
examination in cases of PCFCL or PCMZL, approximately
10% of patients with PCFCL have bone marrow involve-
ment [14]. Furthermore, bone marrow involvement was
associated with significantly inferior disease-specific
survival. Therefore, in the opinion of this author, bone mar-
row examination is justified in cases of PCFCL. While the
TNM staging classification describes the extent of disease,
staging in CBCL is of limited prognostic value, as the dis-
ease histology is the major determinant in risk-stratification.
This is highlighted by a population-based study which iden-
tified histology and the site of skin involvement as important
prognostic factors [15]. In contrast, the International Extra-
nodal Lymphoma Study Group identified three independent
prognostic factors (i.e., elevated LDH, >2 skin lesions, and
nodular lesions) among patients with PCFCL and PCMZL.
These factors were combined to form the cutaneous lym-
phoma international prognostic index (CLIPI). The absence
of any adverse prognostic factor was associated with a
5-year progression-free survival of 91%. In contrast, the
presence of two or three adverse prognostic factors was
associated with a 5-year progression-free survival of 48%.
As the vast majority of relapses were confined to the skin,
the CLIPI was unable to risk-stratify patients by overall sur-
vival. The most important factor for risk-stratification among
the CBCLs remains the histologic classification. Indolent
CBCL (PCFCL and PCMZL) are associated with 5-year
disease-specific survival 95% [1]. Differences in growth
pattern, the density of centroblasts, and cytogenetic
findings do not appear to provide meaningful prognostic
information. Bcl-2 expression among PCFCL with a diffuse
large B-cell histology may be a notable exception [16]. In
contrast, PCLBCL, LT is associated with a 5-year disease-
specific survival of approximately 50% and with cytogenetic
changes, including translocations involving c-myc, that
confer a poor prognosis among systemic DLBCLs [1,17].
In contrast to patients presenting with only a single
tumor, involvement of multiple sites, on one or both legs, is
associated with a significantly inferior disease-specific
survival [18].
Treatment
As no randomized controlled trials are available, treat-
ment recommendations for CBCL are largely based on
small retrospective studies and institutional experience. The
EORTC and ISCL have published consensus treatment
recommendations that are consistent with NCCN guidelines
[19]. In most cases, optimal patient management requires a
multidisciplinary approach, including dermatology, medical
oncology, and radiation oncology.
PCFCL
For patients with solitary lesions, radiation therapy is
safe and highly affective, with a complete remission rate
approaching 100%. Radiation does not appear inferior to
multiagent chemotherapy among patients with multiple
lesions that can be included in multiple radiation fields
[20]. Although radiation therapy is generally recommended
for patients with a solitary lesion, radiation therapy or
observation (i.e., ‘‘watch and wait’’) are reasonable options
for those patients with multiple lesions. Patients with more
extensive skin involvement are effectively managed with
single-agent rituximab [19]. Multiagent chemotherapy (e.g.,
R-CHOP) is rarely required in the management of PCFCL.
Approximately one-third of patients may relapse following
either radiation or single-agent rituximab, but relapses are
usually confined to the skin and are approached in a
manner similar to that described for the initial manage-
ment of PCFCL.
PCMZL
Patients with PCMZL are approached in a manner analo-
gous to that described in the initial management of PCFCL.
Radiation therapy is associated with a similarly high
response rate for patients with a single or few lesions [19].
Those with more widespread skin involvement may be
observed. Once symptomatic, culprit lesions may be irradi-
ated (or surgically excised). As for PCFCL, single-agent
rituximab may be utilized in patients with symptomatic,
widespread skin lesions. An initial trial of antibiotics for
those with B. burgdorferi-associated PCMZL has been rec-
ommended [21], but is less relevant for North American
patients.
PCLBCL, LT
As previously noted, the natural history of PCLBCL, LT
more closely resembles that of systemic DLBCL. There-
fore, R-CHOP (with or without radiation therapy) is uti-
lized in these patients. Although few reports are available
in the literature, the use of R-CHOP in these patients is
associated with remission (and relapse) rates comparable
to those reported for patients with high-risk systemic
DLBCL [19].
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